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Summary 
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive 
memory and cognitive function impairment as well as behavioural and psychiatric disturbances. 
Pharmaceutical care involves the process of identifying, resolving, and preventing drug-related 
problems, and it is aimed at improving the patient’s quality of life. AD is usually diagnosed in 
elderly patients with comorbidities and, consequently, a variety of drug-related problems may 
occur. Pharmacists should focus on adverse reactions, drug-drug interactions, and adherence in 
patients with AD. The introduction of acetylcholinesterase inhibitors in treatment may be 
associated with adverse effects, such as diarrhoea, muscle cramps, fatigue, nausea, vomiting, 
insomnia, anorexia, headache, and dizziness, which may be transient or require an alternative 
medication. Use of anticholinergic medications, bradycardia causing medications, antipsychotics 
and other medications should be assessed carefully because of potential drug-drug interactions 
with acetylcholinesterase inhibitors, especially rivastigmine. Adherence may be a major drug-
related problem in patients with AD because of the nature of illness and appropriate 
communication between pharmacists and patients or carers requiring adequate skills and 
knowledge. Although AD is increasing in prevalence there is a lack of evidence about the impact 
of pharmaceutical care on the treatment outcomes and quality of life of patients and more research 
is needed in this area. 
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Alzheimer's disease (AD) is a neurodegenerative disorder characterized by 
progressive memory and cognitive function impairment as well as behavioural and 
psychiatric disturbances (1, 2). AD is the most prevalent form of dementia in Europe, and 
the global prevalence of the disease is expected to rise in the next decades (3, 4). 
Increasing disease prevalence is accompanied by rising costs in the healthcare system 
because of medical care utilization. The inclusion of the pharmacist in community-based, 
collaborative practises focused on individuals with AD and involvement of their 
caregivers is expected to improve patients’ clinical outcomes while reducing the costs of 
the disease (5). Pharmacists are well-positioned and available healthcare professionals 
with skills and knowledge to assist patients with AD and their caregivers providing 
pharmaceutical care (6).  
According to the Hepler and Strand definition „pharmaceutical care is the 
responsible provision of drug therapy for the purpose of achieving definite outcomes that 
improve a patient’s quality of life”. These outcomes provide curing a disease, elimination 
or reduction of a patients’ symptomatology, arresting or slowing down a disease process, 
or preventing a disease or symptomatology (7, 8). Pharmaceutical care involves the 
process of identifying potential and actual drug-related problems (DRPs), resolving actual 
DRPs, and preventing DRPs (7-9). Pharmaceutical Care Network Europe (PCNE) gives 
the following definition „a DRP is an event or circumstance involving drug therapy that 
actually or potentially interferes with desired health outcomes” (10). DRPs can be 
classified in many ways; the newest PCNE classification (V9.0) distinguishes problems 
related to treatment effectiveness (no effect or suboptimal effect of drug treatment, the 
existence of untreated symptoms or indication), treatment safety (adverse drug events) 
and others (unnecessary treatment, etc.) (10).  
The majority of people with AD are older than 65 years, and they are more likely 
to have comorbid conditions such as cardiovascular diseases and diabetes (11-13). 
Comorbidities often require long-term use of medications which increase the risk of 
DRPs, including cognitive impairment in patients with AD. This could be associated with 
a lack of adherence which can further worsen the outcomes of therapy (14-17). Moreover, 
low quality of life, poor disease outcomes, and increased hospitalizations and healthcare 
costs have been associated with poor medication adherence in the elderly (16-18).  
When AD is diagnosed, patients and/or their carers are usually faced with a lack of 
understanding of the disease and its progression and treatment. They should be provided 
with information about medications, their indications and dosing regimens, adverse 
effects, and possible interactions. Effective medication management includes: 
management of drug interactions and adverse effects; use of as few medications as 
possible; adherence support and support services for patients and carers (5). 




and education for patients and carers. Also, pharmacists may recognize clinical signs and 
symptoms of AD early-stage or mild cognitive impairment and refer the individuals to 
specialists. It is known that patients with mild cognitive impairment are at increased risk 
of developing AD and may benefit from early treatment (5).  
As the disease progresses, changes occur in behaviour, mood, personality, and the 
ability of the patient to communicate effectively (19). Patients become increasingly in 
need to be assisted intensively with daily activities including feeding, dressing, bathing, 
medicines and behaviour management, as well as incontinence (20, 21). 
Behavioural and psychological symptoms of dementia are often challenging to 
family and carers. Symptoms such as delusions, hallucinations, agitation or aggression, 
depression, anxiety, elation or euphoria, apathy or indifference, disinhibition, irritation or 
lability, a change in eating patterns and „wandering around” are included (19). As the 
disease progresses „sundowningИ occurs, which is the term when people have no sense 
of whether it is day or night, and subsequently, the patients awaken carers as they get up 
and dress in the middle of the night. Moreover, when agitation and aggression occur 
patients can be difficult to control, and this is a frequent reason for admission to long-
term care (19). 
Treatment of Alzheimer's dementia 
Two pharmacological groups are currently licensed for the treatment of the 
symptoms of AD: the acetylcholinesterase inhibitors (AChEIs) donepezil, rivastigmine 
and galantamine, and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine. 
The aim of the treatment is not to cure the disease, but to achieve independence as long 
as possible, maintain function and treat cognitive, non-cognitive, behavioural, and 
psychological symptoms (22). AChEIs are recommended treatment options for mild and 
moderate AD. Memantine is used for the treatment of mild or moderate AD for people 
who cannot take AChEIs and for the treatment of severe disease (19,22). Significant 
improvement in cognition and activities of daily living, global outcomes, and less 
agitation have been observed with memantine (23). Memantine can be used as 
monotherapy or in combination with AChEIs.  
The treatment usually starts with one AChEI. If a response to the medication is not 
seen, or intolerable adverse effects occur, it is justifiable to try another medication from 
the same group (19, 22). When initiating the treatment with an AChEI, improvement is 
expected compared to the pre-treatment function and assessment scores. However, as the 
disease progresses, individual patient performance will probably decline, eventually to a 
stage where the medication will seem to have little or no clinical effect. Nevertheless, 
even in those situations, the patient should stay on medication since functions in activities 





Medication management and patient care 
The introduction of treatment for AD may cause a variety of DRPs. AChEIs should 
be started with caution in patients with the presence of supraventricular cardiac 
conduction impairment, asthma or chronic obstructive pulmonary disease (COPD) and 
risk of peptic ulcer disease. Caution is advised when rivastigmine is prescribed to patients 
with renal impairment or mild to moderate hepatic impairment (6, 19). 
Gastrointestinal adverse effects such as diarrhoea, muscle cramps, fatigue, nausea, 
vomiting, insomnia, anorexia, headache, and dizziness are caused by all AChEIs. 
However, if these symptoms occur, the treatment should be continued since they may 
disappear in a short-term period. If the adverse effects are severe and result in significant 
weight loss, the medication can be taken after food, and/or with an anti-emetic. A 3-month 
assessment period is recommended to test the tolerability and clinical efficacy of one 
medication. If the patient cannot tolerate the effective dose or the medication is not 
effective an alternative should be considered (6, 19). 
If nausea/vomiting occurs during AChEI treatment, domperidone or long-acting 
metoclopramide may be offered. Domperidone is the drug of choice because it does not 
cross the blood–brain barrier or have anticholinergic side effects. It should be taken 
regularly three or four times daily for 3 or 4 days. Thereafter, it should be reduced and 
discontinued along with the mildering of adverse effects (6,19).  
Loperamide may be offered to treat diarrhoea if necessary. The dose and frequency 
are usually titrated to control the adverse effect and then taken regularly. However, 
prolonged duration or too high doses of loperamide may cause constipation (19).  
The adverse effects of memantine include dizziness, headache, confusion, 
hallucinations, and tiredness. If the patient is tired, short naps in the mid-afternoon may 
be helpful and the medication should be taken at night to aid sleep (19). 
The patient should be advised to seek help from the prescriber if side effects of 
AChEIs and memantine are severe and/or debilitating, if signs of urinary flow difficulties 
or asthma worsening, COPD or cardiovascular symptoms, especially blackouts appear 
(19).  
It is necessary to bear in mind that concomitant medications with antimuscarinic 
properties, including antipsychotics, tricyclic antidepressants, furosemide, digoxin, and 
others, may exacerbate or cause confusion in patients with AD (19, 24). 
When new medicines are introduced (including the purchase of over-the-counter 
products for coughs and colds) the pharmacist must be sure that they do not cause 
anticholinergic adverse effects because this will increase confusion, impair memory 
function, and possibly antagonise the effect of the AChEI. Drug-drug interactions should 





Table I  The most important drug-drug interactions in the treatment of Alzheimer’s disease (24). 
 
Interacting medications Recommendation 
Acetylcholine esterase inhibitors (AChEIs) 
Anticholinergic Agents  (i.e. amitriptyline; 
atropine, H2 receptor antagonists, ipratropium, 
ketotifen) 
The therapeutic effect of medications may be diminished. 
Avoid concomitant use if possible. Monitor for treatment 
outcomes.
Antipsychotic Agents  Monitor for the development of extrapyramidal symptoms (e.g., 
generalized rigidity, shuffling gait, facial grimacing) during 
concomitant use.
Beta-Blockers and Bradycardia-Causing Agents 
(i.e. amiodarone, digoxin, diltiazem, fingolimod, 
ivabradine, methyldopa, propafenone, verapamil) 
Avoid the concomitant use of rivastigmine with beta-blockers. 
Monitor for increased bradycardia, syncope, and/or hypotension 
in patients receiving concomitant therapy with beta-blockers or 
bradycardia-causing agents and other AChEIs.  
Corticosteroids (Systemic) Monitor for exacerbation of muscular weakness. Dose 
reduction or tapering of AChEIs may be beneficial in the 
setting of high-dose steroid use. 
Dipyridamole Monitor for decreased pharmacologic effects of AChEIs in 
patients who are also receiving dipyridamole. 
Metoclopramide Avoid the concomitant use of rivastigmine and metoclopramide 
because the risk of extrapyramidal adverse effects may be 
increased
CYP2D6 Inhibitors (i.e bupropion, fluoxetine, 
paroxetine) 
Monitor for increased effects of galantamine if used together 
with a strong CYP2D6 inhibitor
CYP3A4 Inhibitors (i.e. clarithromycin, 
itraconazole, ketoconazole) 
Monitor for increased effects of galantamine if used together 
with a strong CYP3A4 inhibitor
Tobacco (smoked) Monitor for reduced rivastigmine efficacy in patients who 
smoke cigarettes and monitor for increased rivastigmine 
effects/toxicities in patients who quit smoking during 
rivastigmine therapy.
QT-prolonging Agents (i.e. amiodarone, 
chlorpromazine, sotalol, terfenadine, ziprasidone)  
 
Monitor for QTc interval prolongation and ventricular 
arrhythmias (including torsades de pointes) when donepezil is 
used.  Greater risk for ventricular arrhythmias is associated 
with, older age, female sex, bradycardia, hypokalaemia, 
hypomagnesemia, heart disease, and higher drug 
concentrations.
Memantine 
Alkalinizing Agents (i.e.   Potassium Citrate, 
Sodium Bicarbonate, Sodium Citrate, Sodium 
Lactate) 
Monitor for increased effects/toxicity of memantine if co-
administered with alkalinizing agents that increase urinary pH. 
Carbonic Anhydrase Inhibitors (i.e. 
acetazolamide, topiramate, zonisamide) 
Monitor for increased effects/toxicity of memantine if co-
administered with a carbonic anhydrase inhibitor. 
NMDA Receptor Antagonists (i.e. 
dextromethorphan, ketamine)
Monitor for increased memantine adverse effects if combined 
with another NMDA receptor antagonist. 
Trimethoprim Monitor patients for signs and symptoms of myoclonus and/or 
delirium. If adverse effects develop discontinuation or dose 
reduction of one or both agents may be necessary. Impaired 
renal function is possibly associated with adverse effects.




Any medication with CNS effects (e.g. benzodiazepines, opiates, or dopaminergic 
agents) may negatively affect cognitive functioning (19).  
Any agent which has the potential to confuse, e.g. long-acting hypoglycaemic 
agents and non-steroidal anti-inflammatory agents, should be carefully monitored and/or 
withdrawn if possible (19).  
Treatment with AChEIs should be long-term since they delay disease progression 
by at least 6 months and some patients may benefit for periods of greater than 7 years 
(25). These agents prolong the possibility for family or carers to provide care in the home 
environment (26).  
Antipsychotics are commonly prescribed to patients with AD when symptoms of 
agitation and aggression occur. However, the prescribing of antipsychotics may be 
inappropriate and associated with increased morbidity and mortality for as long as it is 
prescribed. Deaths associated with cerebrovascular and cardiovascular events, as well as 
pneumonia have been related to antipsychotic prescribing (27). As previously mentioned, 
highly antimuscarinic agents should be used with caution and their effect should be 
monitored because they can reduce cognitive functioning, and they are linked with 
increased mortality and morbidity (28).  
Medication should be reviewed regularly and unnecessary use of medications 
should be avoided. It is important to ensure that the carer is involved in all aspects of 
medicines use because the carer is usually the person ensuring adherence to any 
medication regimen (19).  
Various herbal supplements were expected to prevent and/or delay the onset of 
dementia. The evidence for improvement in cognitive functioning with ginkgo biloba is 
inconsistent. Ginkgo appears to be safe to use and is well tolerated however concomitant 
use with antithrombotics and anticoagulants should be avoided (29, 30).  The efficacy of 
vitamin E in the prevention or treatment of people with AD has not been supported by 
evidence and the risks benefit ratio may be unfavourable (31).  The dietary supplement 
folic acid, vitamin B12, and iron were not shown to improve cognitive impairment if a 
deficiency has not been identified (19).  
The patient may have swallowing and chewing difficulties when the disease 
progresses. The use of liquid medication formulations may be helpful in some cases. 
However, crushing modified release forms to enable swallowing is not recommended. 
The provision of sip feeds may be useful in patients with reduced food and fluid intake 
(19).  
Carers should be advised to remind patients about regular toileting (on waking and 
after meals and before bed) if control of bowels and bladder are reduced. Skin breakdown 




Exercise should be built into the daily routine, and dementia care environments 
should include areas where people can walk safely on their own. If the patient lives in 
his/her own home or with a carer, the surrounding should be adapted to the patient's 
possibility to move around safely (6, 19, 32).  
Maintaining a healthy diet is important especially in patients with cardiovascular 
risks associated with obesity. For patients who smoke, positive health benefits of stopping 
smoking should be emphasized, and nicotine replacement therapy suggested (6). 
The benefits of social interaction and activities which stimulate memory have been 
shown in patients with AD. Social isolation should be avoided and stimulating activities 
depending on the patient's preference and physical ability such as social groups, local 
choirs, sporting activities should be promoted (6, 32).  
Communicating with people with dementia and their carers and 
supporting adherence 
People with dementia are able to communicate and they may enjoy the opportunity 
to talk to a pharmacist. When accurate and reliable information for medication history is 
needed, patients should be involved, but supporting information may be necessary from 
the caregivers (6, 19).  
When communicating with people with dementia pharmacists should tackle and act 
on preserved memory systems. Following strategies are advisable:  
 Sentences should be simple as well as the vocabulary.  
 Information should be precise and understandable.  
 The pharmacist should check if the patient (and the carer) understood the 
information.  
 Information should be summarised at the end and written information provided.  
 The speech should be slow, clear, and audible (19).  
 
It is very important to offer support to carers since lack of support increases the 
probability of early institutionalisation (33). Information should be offered to patients and 
carers according to the stage of the illness, even if it is not always accepted. Patients or 
carers should understand the purpose of each medication and should be aware of adverse 
effects that may interfere with adherence and especially of those that need to be reported 
immediately. Information about medicines use should be offered to patients and carers in 
a precise manner. Directions such as ‘8 pm’ or ‘after breakfast’ are useful so that dosing 
schedules can be planned according to mealtimes. If a medication is being taken for 
insomnia treatment should be advised to be taken 1 h before bedtime so that the 




Medication regimens should be simplified. If possible, modified release forms with 
once-daily dosing should be preferred to medications with more frequent dosing (5, 6, 
19). 
Patients should always use the same medication brand if possible, since patients 
may remember the shape and colour of the brand and get confused if alternatives are used. 
Memory and/or compliance aids and medication reminders may be helpful for patients 
and carers (19).  
It is important to get confirmation from the patient or carer that all medicines are 
used. If there is non-adherence to one or more medications the reasons for it should be 
established. Usually, the reasons are lack of need for the medication or occurrence of 
adverse effects. Some adverse effects might be mitigated by a change of medication 
timing. I.e. donepezil has been associated with insomnia and/or nightmares which may 
be avoided if the medication is administered in the morning (19). 
Research in pharmaceutical care of patients with Alzheimer's dementia 
Although the role of the pharmacist as a healthcare professional in optimizing 
treatment of patients with AD is significant, the evidence regarding the identification of 
DRPs or the provision of pharmaceutical care by pharmacists in patients with AD is 
scarce. 
A study by Alzubaidi et al. investigated community pharmacists’ knowledge of AD 
and its management, counseling skills, and dispensing patterns in patients with AD in the 
United Arab Emirates (UAE) (34). They revealed that when AD medications were 
requested, 24% of pharmacists reported that they asked the caregiver about the history of 
the disease; however, the questions were not specified. Most pharmacists provided 
counselling infrequently; 29.6% reported no or occasional counselling of patients or 
caregivers. Pharmacists counselling points were usually instructions on medication use 
(48%), the indication of the medication (32.9%), and possible adverse effects (30.8%). 
Verbal communication of information to caregivers was reported by 36% of pharmacists, 
written and verbal communication was reported by 30%, whereas 33.5% did not respond 
to this item. Adherence aids were not given to people with AD or their caregivers by more 
than half (53.5%) of pharmacists and adherence to prescribed medications was not 
assessed routinely. The interventions were informing the caregivers (7.1%) and 
consulting with the physician (7.1%) when an adherence problem was discovered (34).  
Another study by Pfister et al investigated the occurrence and character of DRPs in 
older hospitalized people with dementia and cognitive impairment. They found that 
ineffective drug/inappropriate drug and unnecessary drug therapy were the most common 






Pharmacists are accessible healthcare professionals with adequate skills and 
knowledge to provide pharmaceutical care for patients with AD. Increased involvement 
of pharmacists in the provision of care of patients with AD could improve their treatment 
outcomes and quality of life. With the expected increase in the prevalence of the disease 
optimizing pharmaceutical care in patients with AD will be beneficial for the patients and 
the healthcare system. However, more evidence is needed to reveal the impact of 
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Alchajmerova bolest (AD) je neurodegenerativni poremećaj koji karakteriše progresivno 
oštećenje pamćenja i kognitivnih funkcija, kao i bihejvioralni poremećaj pacijenta. Farmaceutska 
zdravstvena zaštita je proces koji uključuje identifikaciju, rešavanje i sprečavanje pojave 
problema povezanih sa terapijom sa ciljem postizanja ishoda koji poboljšavaju kvalitet života 
pacijenta. AD se obično dijagnostikuje kod starijih pacijenata sa komorbiditetima i mogu se 
pojaviti različiti problemi u vezi sa terapijom. Potrebno je da farmaceuti posebno obrate pažnju 
na neželjene reakcije na lek, interakcije lekova i adherencu kod pacijenata sa AD. Uvođenje 
inhibitora acetilholinesteraze u terapiju može biti povezano sa neželjenim reakcijama na lek, kao 
što su dijareja, mišićni grčevi, umor, mučnina, povraćanje, nesanica, anoreksija, glavobolja i 
vrtoglavica, koji mogu biti prolazni ili zahtevati promenu leka. Upotrebu antiholinergičkih 
lekova, lekova koji izazivaju bradikardiju, antipsihotika i drugih lekova treba pažljivo razmatrati 
zbog potencijalnih interakcija navedenih lekova sa inhibitorima acetilholinesteraze, posebno 
rivastigminom. Adherenca može biti važan problem u vezi sa terapijom kod pacijenata sa AD 
zbog prirode bolesti, a veštine i znanja farmaceuta su neophodni da bi komunikacija sa 
pacijentima ili negovateljima bila odgovarajuća. Iako se učestalost AD povećava, nedostaje 
dokaza o uticaju farmaceutske zdravstvene zaštite na ishode terapije i kvalitet života pacijenata, 
stoga je potrebno više istraživanja u ovoj oblasti. 
 
Ključne reči:  Alchajmerova demencija, farmaceutska zdravstvena zaštita,  
    neželjene reakcije na lek, interakcije, adherenca. 
 
